Christina M. Andrews
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Christina M. Andrews has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Amanda J. Abraham
School of Public and International Affairs, University of Georgia, Athens, Georgia
6 shared publications Melissa A. Westlake
6 shared publicationsColleen M. Grogan
4 shared publications- Colleen M. Grogan
University of Chicago
3 shared publications Harold A. Pollack
Harold A. Pollack is the Helen Ross Professor in the School of Social Service Administration, University of Chicago
3 shared publications- Peter D. Friedmann
Department of Healthcare Delivery and Population Science, University of Massachusetts Chan Medical School - Baystate, Springfield, MA, United States
3 shared publications
Latest Publications
- Open Access
- 21 July 2026
- Published by Wolters Kluwer Health in Medical Care
- Vol. 64 (11) , 801-810
Continuity of Medications for Opioid Use Disorder in States With and Without Medicaid Prescription Cap Policies
Background: Medicaid prescription cap policies persist in 12 states; however, it is unclear how they affect the quality of opioid use disorder (OUD) treatment. Objectives: To examine the association between cap policies and the continuity in receipt of medication for OUD (MOUD) treatment in Medicaid. Methods: Using 2016–2021 T-MSIS Analytical Files data from 37 states, we identified nondual adult (18–64 y) Medicaid enrollees diagnosed with OUD who received MOUD. The exposure was the state’s Medicaid prescription cap policy status. The main outcome was a binary variable for MOUD continuity, overall and by type, defined as no treatment gap exceeding 7 consecutive days during a 180-day observation period. We estimated risk ratios for MOUD continuity using modified Poisson regression models, adjusting for individual and state-level covariates to test associations. Results: Nearly half the sample was female, and the mean age was 37 years. MOUD continuity ranged from 40.7% to 44.3% in states without cap policies and 37.5%–39.6% in cap states. Compared with enrollees in noncap states, those in cap states had a 12% higher likelihood of experiencing at least 1 MOUD treatment gap [risk ratio (RR)=1.12; 95% CI: 1.12–1.13]. These findings were consistent for buprenorphine and methadone. Factors associated with overall MOUD discontinuity included younger age, male sex, living in nonmetropolitan areas, and having 3 or more comorbidities. Conclusions: Prescription caps were associated with reduced continuity of MOUD, overall and for buprenorphine and methadone, suggesting that revising or removing these policies could improve OUD quality metrics in Medicaid.
- 21 July 2026
- Published by Wolters Kluwer Health in Medical Care
- Vol. 64 (11) , 801-810
Open AccessContinuity of Medications for Opioid Use Disorder in States With and Without Medicaid Prescription Cap Policies
Background: Medicaid prescription cap policies persist in 12 states; however, it is unclear how they affect the quality of opioid use disorder (OUD) treatment. Objectives: To examine the association between cap policies and the continuity in receipt of medication for OUD (MOUD) treatment in Medicaid. Methods: Using 2016–2021 T-MSIS Analytical Files data from 37 states, we identified nondual adult (18–64 y) Medicaid enrollees diagnosed with OUD who received MOUD. The exposure was the state’s Medicaid prescription cap policy status. The main outcome was a binary variable for MOUD continuity, overall and by type, defined as no treatment gap exceeding 7 consecutive days during a 180-day observation period. We estimated risk ratios for MOUD continuity using modified Poisson regression models, adjusting for individual and state-level covariates to test associations. Results: Nearly half the sample was female, and the mean age was 37 years. MOUD continuity ranged from 40.7% to 44.3% in states without cap policies and 37.5%–39.6% in cap states. Compared with enrollees in noncap states, those in cap states had a 12% higher likelihood of experiencing at least 1 MOUD treatment gap [risk ratio (RR)=1.12; 95% CI: 1.12–1.13]. These findings were consistent for buprenorphine and methadone. Factors associated with overall MOUD discontinuity included younger age, male sex, living in nonmetropolitan areas, and having 3 or more comorbidities. Conclusions: Prescription caps were associated with reduced continuity of MOUD, overall and for buprenorphine and methadone, suggesting that revising or removing these policies could improve OUD quality metrics in Medicaid.
- Open Access
- 18 October 2025
- Published by Springer Nature in Journal of Racial and Ethnic Health Disparities
- p. 1-10
Racial and Ethnic Community Composition and Geographic Distance to Substance Use Disorder Treatment Across the Rural and Urban Divide
Objectives: To examine whether geographic driving distance to substance use disorder (SUD) treatment varies by racial/ethnic concentration of residents in urban and rural communities. Methods: We conducted a cross-sectional analysis at the ZIP Code Tabulation Area (ZCTA) level using data from the Substance Abuse and Mental Health Service Administration (SAMHSA) 2021 Behavioral Health Treatment Services Locator. We conducted logistic regressions to examine rural–urban differences in driving distances to SUD treatment facilities among ZCTAs with a high relative concentration of a single racial/ethnic group. Results: Urban ZCTAs with a high concentration of Black or Hispanic residents had greater odds of having a SUD treatment facility (odds ratio [OR] = 2.39, confidence interval [CI] [2.04, 2.81] and OR = 2.20, CI [1.86, 2.61], respectively), while ZCTAs with a high concentration of White and American Indian/Alaska Natives (AI/AN) communities had lower odds (OR = 0.26, CI [0.23, 0.30] and OR = 0.55, CI [0.47, 0.63], respectively), compared to all other ZCTAs. Conclusions: SUD treatment facilities, which have historically faced heavy stigmatization, are more likely to be placed in communities with a high concentration of Black and Hispanic residents. Consequently, White ZCTAs were less likely to have a SUD treatment facility nearby than other communities. This is important evidence to explore in determining whether stigmatization may play a role in treatment availability.
- 18 October 2025
- Published by Springer Nature in Journal of Racial and Ethnic Health Disparities
- p. 1-10
Open AccessRacial and Ethnic Community Composition and Geographic Distance to Substance Use Disorder Treatment Across the Rural and Urban Divide
Objectives: To examine whether geographic driving distance to substance use disorder (SUD) treatment varies by racial/ethnic concentration of residents in urban and rural communities. Methods: We conducted a cross-sectional analysis at the ZIP Code Tabulation Area (ZCTA) level using data from the Substance Abuse and Mental Health Service Administration (SAMHSA) 2021 Behavioral Health Treatment Services Locator. We conducted logistic regressions to examine rural–urban differences in driving distances to SUD treatment facilities among ZCTAs with a high relative concentration of a single racial/ethnic group. Results: Urban ZCTAs with a high concentration of Black or Hispanic residents had greater odds of having a SUD treatment facility (odds ratio [OR] = 2.39, confidence interval [CI] [2.04, 2.81] and OR = 2.20, CI [1.86, 2.61], respectively), while ZCTAs with a high concentration of White and American Indian/Alaska Natives (AI/AN) communities had lower odds (OR = 0.26, CI [0.23, 0.30] and OR = 0.55, CI [0.47, 0.63], respectively), compared to all other ZCTAs. Conclusions: SUD treatment facilities, which have historically faced heavy stigmatization, are more likely to be placed in communities with a high concentration of Black and Hispanic residents. Consequently, White ZCTAs were less likely to have a SUD treatment facility nearby than other communities. This is important evidence to explore in determining whether stigmatization may play a role in treatment availability.
- Open Access
- 5 September 2025
- Published by American Medical Association (AMA) in JAMA Health Forum
- Vol. 6 (9) , e253239
Coverage for Opioid Use Disorder Medications in Medicaid Managed Care
This cross-sectional study describes the distribution of state Medicaid managed care plans providing and managing opioid use disorder medication benefits to beneficiaries in 2023.
- 5 September 2025
- Published by American Medical Association (AMA) in JAMA Health Forum
- Vol. 6 (9) , e253239
Open AccessCoverage for Opioid Use Disorder Medications in Medicaid Managed Care
This cross-sectional study describes the distribution of state Medicaid managed care plans providing and managing opioid use disorder medication benefits to beneficiaries in 2023.
- 4 September 2025
- Published by Elsevier in Public Health
- Vol. 248, 105925
Prevalence of depressive symptoms and serious suicidal thoughts among adolescents aged 12–17 by rurality in the United States
- 4 September 2025
- Published by Elsevier in Public Health
- Vol. 248, 105925
Prevalence of depressive symptoms and serious suicidal thoughts among adolescents aged 12–17 by rurality in the United States
- Open Access
- 8 June 2025
- Published by Elsevier in Journal of Substance Use and Addiction Treatment
- Vol. 176, 209738
Medicaid health home design and buprenorphine receipt, 2009–2020
- 8 June 2025
- Published by Elsevier in Journal of Substance Use and Addiction Treatment
- Vol. 176, 209738
Open AccessMedicaid health home design and buprenorphine receipt, 2009–2020
- Open Access
Crafting effective regulatory policies for psychedelics: What can be learned from the case of cannabis?
The turn of the century brought a resurgence of interest in psychedelics as a treatment for addiction and other psychiatric conditions, accompanied by extensive positive media attention and private equity investment. Government regulatory bodies in Australia, Israel, Canada and the United States now permit use of psychedelics for medical purposes. In the United States, citizen action and corporate financing have led to petitions and ballot initiatives to legalize psilocybin and other psychedelics for medical and recreational use. Given this momentum, policymakers must grapple with important questions that define whether and how psychedelics are made available to the public, as well as how companies produce and promote them. The current push to broaden the production, sale, and use of psychedelics bears many parallels to the movement to legalize cannabis in the United States and other nations—most notably, the use of poorly‐evidenced therapeutic claims to create a de facto recreational market via the health care system. Experience with cannabis highlights the value of debating the question of legalization for nonmedical use as such rather than misrepresenting it as a medical issue. The lessons of cannabis policy also suggest a need to challenge hyping of psychedelic research findings; to promote rigorous clinical research on dosing and potency; to minimize the influence of for‐profit industry in shaping policies to their economic advantage; and to coordinate federal, state, and local governments to regulate the manufacture, sale and distribution of psychedelic drugs (regardless of whether they are legalized for medical and/or recreational use).
Open AccessCrafting effective regulatory policies for psychedelics: What can be learned from the case of cannabis?
The turn of the century brought a resurgence of interest in psychedelics as a treatment for addiction and other psychiatric conditions, accompanied by extensive positive media attention and private equity investment. Government regulatory bodies in Australia, Israel, Canada and the United States now permit use of psychedelics for medical purposes. In the United States, citizen action and corporate financing have led to petitions and ballot initiatives to legalize psilocybin and other psychedelics for medical and recreational use. Given this momentum, policymakers must grapple with important questions that define whether and how psychedelics are made available to the public, as well as how companies produce and promote them. The current push to broaden the production, sale, and use of psychedelics bears many parallels to the movement to legalize cannabis in the United States and other nations—most notably, the use of poorly‐evidenced therapeutic claims to create a de facto recreational market via the health care system. Experience with cannabis highlights the value of debating the question of legalization for nonmedical use as such rather than misrepresenting it as a medical issue. The lessons of cannabis policy also suggest a need to challenge hyping of psychedelic research findings; to promote rigorous clinical research on dosing and potency; to minimize the influence of for‐profit industry in shaping policies to their economic advantage; and to coordinate federal, state, and local governments to regulate the manufacture, sale and distribution of psychedelic drugs (regardless of whether they are legalized for medical and/or recreational use).
- 1 January 2024
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 43 (1) , 55-63
Medicaid Managed Care Prior Authorization For Buprenorphine Tied To State Partisanship And Health Plan Profit Status, 2018
Buprenorphine is among the most effective drugs for treating opioid use disorder, yet only a quarter of Americans who need it receive it. Requiring prior authorization has been identified as an important barrier to buprenorphine access. However, the practice remains widespread in Medicaid-the largest insurer of Americans with opioid use disorder. In this study, we examined how prior authorization for buprenorphine is related to plan structure and state political environment, using data on all 266 comprehensive Medicaid managed care plans active in 2018. We found substantial variation in prior authorization use across states, with all plans requiring prior authorization in eleven states and no plans requiring it in thirteen other states. We found that for-profit plans and those located in Republican states were more likely to impose prior authorization policies. Our findings suggest that managed care plans' decisions regarding use of prior authorization may be shaped by internal pressures to control costs, as well as by differing partisan stances regarding the need to prevent criminal diversion of buprenorphine.
- 1 January 2024
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 43 (1) , 55-63
Medicaid Managed Care Prior Authorization For Buprenorphine Tied To State Partisanship And Health Plan Profit Status, 2018
Buprenorphine is among the most effective drugs for treating opioid use disorder, yet only a quarter of Americans who need it receive it. Requiring prior authorization has been identified as an important barrier to buprenorphine access. However, the practice remains widespread in Medicaid-the largest insurer of Americans with opioid use disorder. In this study, we examined how prior authorization for buprenorphine is related to plan structure and state political environment, using data on all 266 comprehensive Medicaid managed care plans active in 2018. We found substantial variation in prior authorization use across states, with all plans requiring prior authorization in eleven states and no plans requiring it in thirteen other states. We found that for-profit plans and those located in Republican states were more likely to impose prior authorization policies. Our findings suggest that managed care plans' decisions regarding use of prior authorization may be shaped by internal pressures to control costs, as well as by differing partisan stances regarding the need to prevent criminal diversion of buprenorphine.
- 6 May 2023
- Published by Elsevier in Journal of Substance Use and Addiction Treatment
- Vol. 150, 209064
Allocation of federal funding to address the opioid overdose crisis in the criminal legal system
- 6 May 2023
- Published by Elsevier in Journal of Substance Use and Addiction Treatment
- Vol. 150, 209064
Allocation of federal funding to address the opioid overdose crisis in the criminal legal system